Source comparison
Sermorelin Bone Density Results Timeline: Comparison
0–8 weeks Serum IGF-1 ↑ 30–50% from baseline; osteocalcin ↑ 25–40%; no change in CTX yet None. Bone remodeling cycle hasn't completed Early IGF-1 rise doesn't translate to structural change yet; this is where most people mistakenly assume 'it's not working' To
This comparison does not assign a generated winner or score.
- 0–8 weeks
- Serum IGF-1 ↑ 30–50% from baseline; osteocalcin ↑ 25–40%; no change in CTX yet
- None. Bone remodeling cycle hasn't completed
- Early IGF-1 rise doesn't translate to structural change yet; this is where most people mistakenly assume 'it's not working'
- Too early to assess bone density outcomes. Focus on verifying IGF-1 response
- 8–16 weeks
- Osteocalcin peaks at +40–60%; CTX begins declining (−15 to −25%); IGF-1 plateau at new baseline
- Still none. First BMU cycle completing but not yet reflected in DEXA
- Formation markers peak before resorption markers decline; this is the biochemical 'sweet spot' before structural changes appear
- Biochemical confirmation that bone remodeling is shifting toward net formation
- 6–9 months
- Osteocalcin remains elevated (+35–50%); CTX stable at reduced level (−20 to −30%)
- Lumbar spine BMD ↑ 1.5–3.0%; femoral neck minimal or no change
- First measurable DEXA improvements; trabecular bone (spine) responds before cortical bone (hip)
- First objective evidence of structural bone density improvement
- 12–18 months
- Markers stabilize at new set point; osteocalcin +30–45%, CTX −25–35%
- Lumbar spine BMD ↑ 3.0–4.5%; femoral neck ↑ 1.5–2.5%
- Peak gains occur here; continued use maintains but doesn't amplify further without protocol adjustment
- Maximal bone density response achieved. Maintain or adjust protocol based on goals